Cancers, Vol. 15, Pages 3774: Establishment and Molecular Characterization of an In Vitro Model for PARPi-Resistant Ovarian Cancer
Cancers, Vol. 15, Pages 3774: Establishment and Molecular Characterization of an In Vitro Model for PARPi-Resistant Ovarian Cancer
Cancers doi: 10.3390/cancers15153774
Authors:
Daniel Martin Klotz
Franziska Maria Schwarz
Anna Dubrovska
Kati Schuster
Mirko Theis
Alexander Krüger
Oliver Kutz
Theresa Link
Pauline Wimberger
Stephan Drukewitz
Frank Buchholz
Jürgen Thomale
Jan Dominik Kuhlmann
Overcoming PARPi resistance is a high clinical priority. We established and characterized comparative in vitro models of acquired PARPi resistance, derived from either a BRCA1-proficient or BRCA1-deficient isogenic background by long-term exposure to olaparib. While parental cell lines already exhibited a certain level of intrinsic activity of multidrug resistance (MDR) proteins, resulting PARPi-resistant cells from both models further converted toward MDR. In both models, the PARPi-resistant phenotype was shaped by (i) cross-resistance to other PARPis (ii) impaired susceptibility toward the formation of DNA-platinum adducts upon exposure to cisplatin, which could be reverted by the drug efflux inhibitors verapamil or diphenhydramine, and (iii) reduced PARP-trapping activity. However, the signature and activity of ABC-transporter expression and the cross-resistance spectra to other chemotherapeutic drugs considerably diverged between the BRCA1-proficient vs. BRCA1-deficient models. Using dual-fluorescence co-culture experiments, we observed that PARPi-resista...
Source: Cancers - Category: Cancer & Oncology Authors: Daniel Martin Klotz Franziska Maria Schwarz Anna Dubrovska Kati Schuster Mirko Theis Alexander Kr üger Oliver Kutz Theresa Link Pauline Wimberger Stephan Drukewitz Frank Buchholz J ürgen Thomale Jan Dominik Kuhlmann Tags: Article Source Type: research
More News: Benadryl | Cancer | Cancer & Oncology | Multidrug Resistance | Ovarian Cancer | Ovaries | Verapamil